Prostate-Specific Antigen (PSA) Test Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Prostate-Specific Antigen (PSA) Test Market: By Type (CLIA Method, ELISA Method) By Application (Screening, Post-treatment Monitoring, Others) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Prostate-Specific Antigen (PSA) Test Market size is estimated to be valued at USD 3,276.9 Million in 2021 and is poised to grow at a significant CAGR of 11.5% over 2022-2028. PSA or prostate-specific antigen testing determines the amount of PSA in human blood. The prostate is a tiny gland in a man’s reproductive system placed underneath the bladder. Prostate-specific antigen is a glycoprotein released by prostatic epithelial cells, and PSA is either attached to other cells or freely circulates throughout the body. The CLIA method segment is anticipated to grow at a significant CAGR over the forecast years, owing to CLIA solutions being frequently used in identifying chronic diseases such as infectious disease, autoimmune disease, cardiovascular disease, diabetes, obesity, and prostate cancer. CLIA is also utilised for therapeutic medication monitoring by several pharmaceutical corporations and research institutions. Rising awareness of the need for early detection of chronic diseases and increased medication discovery and development operations by pharmaceutical firms are viewed as high-impact key drivers for the Segment. Increase in prostate cancer among men, who are over 50 years in age. Furthermore, the adoption of various assay-based methods and various new inventions for the diagnosis of prostate cancer has raised the demand for industry’s growth over the forecasting period.

Key Developments:

In September 2021: Boston Scientific Corporation, the leading medical device manufacturer, announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC) of the liver.

Prostate-Specific Antigen (PSA) Test Market

MARKET SUMMARY
-
11.5%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 11.5%
  • Largest Market– North American
  • Fastest Growing Market– Asia-Pacific

Prostate-Specific Antigen (PSA) Test Market

  • The prostate-specific antigen (PSA) test market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The prostate-specific antigen (PSA) test market is segmented based on types, applications, and geography.
Key Players
  • Abbott
  • Siemens Healthcare
  • DiaSorin
  • Roche
  • Beckman Coulter
Prostate-Specific Antigen (PSA) Test Market

The market for prostate-specific antigen testing is expanding due to a rise in the elderly population. Additionally, rising public awareness about the benefits of prostate cancer screening, technological advancements in testing and treating prostate cancer, and various reimbursement policies for prostate cancer treatments in different developed and developing regions are influencing the growth of the prostate-specific antigen market, according to the Census Bureau’s 2017 National Population Projections, all baby boomers will be over 65, implying that one in every five people would be of retirement age. This reflects an increase in the geriatric population.


North America Got Significant Share

Prostate-Specific Antigen (PSA) Test Market

The Prostate-Specific Antigen (PSA) Test market in North America is likely to hold the highest revenue share in 2021, and the same trend is expected over the forecast period due to the ensuing high mortality rate in various developed nations, as well as the growing prevalence of prostate cancer in this area, will drive the expansion of the Prostate Specific Antigen (PSA) Testing Market in the future years. Furthermore, increased government attention to prostate cancer diagnosis and improvement in healthcare is expected to drive the expansion of the region's Prostate Specific Antigen (PSA) Testing Market. Moreover, according to the research study in North America older males and non-Hispanic Black men have a higher risk of developing prostate cancer. It is uncommon in men under 40 and is diagnosed in about 6 out of 10 men who are 65 or older. The typical diagnostic age for men is 66.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Prostate-Specific Antigen (PSA) Test Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The prostate-specific antigen (PSA) test market is projected to expand at a CAGR of 11.5% during the forecast period

Abbott, Siemens Healthcare, DiaSorino, Roche, Beckman Coulter, Mediwatch (LABORIE), BodiTech-Bristol-Myers Squibb Company, GE Healthcare, Endocare, GlaxoSmithKline, Anixa Biosciences, Ortho Clinicals, Fujirebio, Pharmacia Delfia

North America is the fastest-growing region for prostate-specific antigen (PSA) test market


Report

Table Of Content

1. Executive Summary
2. Prostate-Specific Antigen (PSA) Test Market Introduction
2.1. Global Prostate-Specific Antigen (PSA) Test Market – Taxonomy
2.2. Global Prostate-Specific Antigen (PSA) Test Market –Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By Region
3. Global Prostate-Specific Antigen (PSA) Test Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Prostate-Specific Antigen (PSA) Test Market Dynamic Factors – Impact Analysis
3.6. Global Prostate-Specific Antigen (PSA) Test Market – Competition Landscape
4. Global Prostate-Specific Antigen (PSA) Test Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Prostate-Specific Antigen (PSA) Test Market, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. CLIA Method
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. ELISA Method
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Prostate-Specific Antigen (PSA) Test Market, By Application, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Screening
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Post-treatment Monitoring
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Prostate-Specific Antigen (PSA) Test Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Prostate-Specific Antigen (PSA) Test Market – Opportunity Analysis Index, By Type, By Application, and Region, 2022 – 2028
8. North America Prostate-Specific Antigen (PSA) Test Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. CLIA Method
8.1.2. ELISA Method
8.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Screening
8.2.2. Post-treatment monitoring
8.2.3. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Prostate-Specific Antigen (PSA) Test Market – Opportunity Analysis Index, By Type, By Application, and Country, 2022 – 2028
8.5. North America Prostate-Specific Antigen (PSA) Test Market Dynamics – Trends
9. Europe Prostate-Specific Antigen (PSA) Test Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. CLIA Method
9.1.2. ELISA Method
9.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Screening
9.2.2. Post-treatment monitoring
9.2.3. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Europe Prostate-Specific Antigen (PSA) Test Market – Opportunity Analysis Index, By Type, By Application, and Country, 2022 – 2028
9.5. Europe Prostate-Specific Antigen (PSA) Test Market Dynamics – Trends
10. Asia-Pacific Prostate-Specific Antigen (PSA) Test Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. CLIA Method
10.1.2. ELISA Method
10.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Screening
10.2.2. Post-treatment monitoring
10.2.3. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Prostate-Specific Antigen (PSA) Test Market – Opportunity Analysis Index, By Type , By Application, and Country, 2022 – 2028
10.5. Asia-Pacific Prostate-Specific Antigen (PSA) Test Market Dynamics – Trends
11. Latin America Prostate-Specific Antigen (PSA) Test Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. CLIA Method
11.1.2. ELISA Method
11.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Screening
11.2.2. Post-treatment monitoring
11.2.3. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Prostate-Specific Antigen (PSA) Test Market – Opportunity Analysis Index, By Type , By Application, and Country, 2022 – 2028
11.5. Latin America Prostate-Specific Antigen (PSA) Test Market Dynamics – Trends
12. Middle East and Africa Prostate-Specific Antigen (PSA) Test Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. By Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. CLIA Method
12.1.2. ELISA Method
12.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Screening
12.2.2. Post-treatment monitoring
12.2.1. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Prostate-Specific Antigen (PSA) Test Market – Opportunity Analysis Index, By Type , By Application, and Country, 2022 – 2028
12.5. MEA Prostate-Specific Antigen (PSA) Test Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott
13.2.2. Siemens Healthcare
13.2.3. DiaSorin
13.2.4. Roche
13.2.5. Beckman Coulter
13.2.6. Mediwatch (LABORIE)
13.2.7. BodiTech
13.2.8. Bristol-Myers Squibb Company
13.2.9. GE Healthcare
13.2.10. Endocare
13.2.11. GlaxoSmithKline
13.2.12. Anixa Biosciences
13.2.13. Ortho Clinicals
13.2.14. Fujirebio
13.2.15. Pharmacia Delfia
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Abbott
  • Siemens Healthcare
  • DiaSorin
  • Roche
  • Beckman Coulter
  • Mediwatch (LABORIE)
  • BodiTech
  • Bristol-Myers Squibb Company
  • GE Healthcare
  • Endocare
  • GlaxoSmithKline
  • Anixa Biosciences
  • Ortho Clinicals
  • Fujirebio
  • Pharmacia Delfia

Description

Prostate-Specific Antigen (PSA) Test Market size is estimated to be valued at USD 3,276.9 Million in 2021 and is poised to grow at a significant CAGR of 11.5% over 2022-2028. PSA or prostate-specific antigen testing determines the amount of PSA in human blood. The prostate is a tiny gland in a man’s reproductive system placed underneath the bladder. Prostate-specific antigen is a glycoprotein released by prostatic epithelial cells, and PSA is either attached to other cells or freely circulates throughout the body. The CLIA method segment is anticipated to grow at a significant CAGR over the forecast years, owing to CLIA solutions being frequently used in identifying chronic diseases such as infectious disease, autoimmune disease, cardiovascular disease, diabetes, obesity, and prostate cancer. CLIA is also utilised for therapeutic medication monitoring by several pharmaceutical corporations and research institutions. Rising awareness of the need for early detection of chronic diseases and increased medication discovery and development operations by pharmaceutical firms are viewed as high-impact key drivers for the Segment. Increase in prostate cancer among men, who are over 50 years in age. Furthermore, the adoption of various assay-based methods and various new inventions for the diagnosis of prostate cancer has raised the demand for industry’s growth over the forecasting period.

Key Developments:

In September 2021: Boston Scientific Corporation, the leading medical device manufacturer, announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC) of the liver.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX